Abiopharma

🔍 Regan Andrew (Director)

Company: CDT Equity Inc. (CDT)

Report Date: 2026-07-30

Detailed Transactions and Holdings:

• Acquired 5,436,830 shares of Common Stock (Direct)
  Date: 2026-08-28 | Code: J | equity_swap_involved: 0 | shares_owned_after: 5,693,223.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3
• Sold 290 shares of Common Stock (Direct)
  Date: 2026-08-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,692,933.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | shares_owned_after: 5,600.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | nature_of_ownership: By Manoira Corporation | shares_owned_after: 773.00 | Footnotes: F4
• Acquired 5,436,830 shares of Pre-Funded Warrants at $0.0001 per share (Derivative)
  Date: 2026-07-30 | Code: J | equity_swap_involved: 0 | shares_owned_after: 5,436,830.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F7, F1, F1, F4
• Sold 5,436,830 shares of Pre-Funded Warrants at $0.0001 per share (Derivative)
  Date: 2026-08-28 | Code: X | Exercise: 2026-08-28 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F7, F1, F1, F4

Footnotes:

• F1: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.
• F2: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.
• F3: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.
• F4: Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.
• F5: These shares of Common Stock are owned of record by Manoira.
• F6: Corvus exercised the Pre-Funded Warrants on a cashless basis, which resulted in the Issuer withholding 290 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants to pay the exercise price.
• F7: The Pre-Funded Warrants have been exercised in full.